All relevant data are within the paper and its Supporting Information files.

Introduction {#sec004}
============

Bevacizumab (BV), a humanized recombinant monoclonal antibody against vascular endothelial growth factor (VEGF), was approved by the US food and drug administration (FDA) on the market based on its effectiveness in metastatic cancers. Bevacizumab specifically binds to the VEGF-A protein, thereby inhibiting the process of angiogenesis.

Many randomized controlled trials (RCTs) and several meta-analyses on the efficacy and safety of BV in different tumor types have been published. From these studies, while BV added to chemotherapy improved progression free survival (PFS) and overall survival (OS), there was no significant influence on quality of life (QOL) but there were increased risks of serious adverse drug reactions (ADRs). There was controversy on the dose-effect relations of BV and ADRs: while some studies found increased risks of the occurrence of some ADRs e.g. all grade hypertension (RR: 7.5, 95% CI: 4.2--13.4 vs. RR: 3.0, 95%CI: 2.2--4.2), and high-grade bleeding (RR: 3.02, 95% CI:1.85--4.95 vs. RR: 1.27,95%CI: 0.95--1.7) \[[@pone.0136324.ref001],[@pone.0136324.ref002]\] for the high-dose BV compared to low-dose, whereas a recent safety meta-analysis of 13 heterogeneous trials did not \[[@pone.0136324.ref003]\]. However, defining which of any benefited more or less from BV has not been extensively studied. Therefore, and because there have been new RCTs published after the latest published meta-analysis \[[@pone.0136324.ref004]\], we conducted a large meta-analysis to examine predictive factors for BV efficacy and safety by performing a series of subgroup, meta-regression and sensitivity analyses. In addition, we systematically assessed heterogeneity and publication bias.

Methods {#sec005}
=======

Data source {#sec006}
-----------

All published RCTs on the efficacy and safety of BV in different tumor types were collected by conducting a literature search using PubMed, EMBASE, Cochrane and Clinical [trials.gov](http://trials.gov/) database with the keywords shown in [S1 Table](#pone.0136324.s005){ref-type="supplementary-material"} **(See Appendix)**. Furthermore, we searched abstracts and virtual meeting presentations from websites of the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Federation of European Cancer Societies (FECS) and San Antonio Breast Cancer Symposium (SABCS) to identify relevant RCTs. Further information was retrieved through a manual search of references from recent meta-analyses and relevant published trials.

Inclusion and exclusion criteria {#sec007}
--------------------------------

All phase 2 or 3 RCTs were included in our study if there was a direct comparison between BV in combination with adjuvant therapy and adjuvant therapy alone available (experimental arm: BV plus adjuvant therapy agent (s); control arm: adjuvant therapy with or without placebo) in patients with metastatic cancers. Only publications in English language and from January 1966 to 7^th^ of May 2014 were considered. Trials in pediatric populations and trials where BV was used for the treatment of macular retinopathy and brain tumors were excluded from this meta-analysis because of different outcome measurements. Two investigators (FA and AdB) independently applied the inclusion and exclusion criteria to select the relevant trials.

Data extraction and clinical end points {#sec008}
---------------------------------------

Data extraction was conducted in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance (**[S1 PRISMA Checklist](#pone.0136324.s001){ref-type="supplementary-material"}**) \[[@pone.0136324.ref005]\]. The clinical end points used for this study were PFS, defined as the time from random assignment to first reported progression or all-cause mortality in the absence of previously documented tumor progression, OS, defined as the time from random assignment to death which can be from any cause, censoring patients who had alive at the date last visit, overall response rate (ORR), defined as the sum of partial and complete response rates (according to the Response Evaluation Criteria in Solid Tumors) \[[@pone.0136324.ref006]\], ADRs were graded according to the Common Toxicity Criteria version 3 ([http://ctep.cancer.gov](http://ctep.cancer.gov/)) and QOL assessed at baseline and during the follow-up time until disease progression.

Hazard Ratios (HRs) for PFS and OS, median PFS (mPFS) and median OS (mOS), the number of patients with ORR and the number of adverse drug reactions (ADRs) were extracted from the papers. Furthermore, the first author, year of publication, trial design characteristics (study phase, outcome measures, tumor type, therapy regime for each arm, dose of treatment, median time of follow-up, median duration of BV therapy and time points of response assessment), patient characteristics (median age and number of patients evaluated for efficacy and safety in each arm) were extracted. In case of missing data for HR as a point estimate in trials, authors were contacted via email to provide the necessary information.

Risk of bias assessment {#sec009}
-----------------------

Quality assessment of the publications included was performed independently by three investigators using the Cochrane Collaboration's tool (<http://handbook.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm>). This means that the trials were rated for domains of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of primary outcomes (PFS, OS, ORR) assessment, blinding of secondary outcomes (safety and QOL) assessment, incomplete PFS, OS and ORR data, incomplete safety data, selective reporting and other biases. In the case of any disagreement between investigators to rate the quality of each trial consensus was reached. When there was insufficient information to permit the evaluation of the quality it was rated as unclear (uncertain risk of bias).

Data analysis {#sec010}
-------------

Overall pooled estimates, together with 95% confidence intervals (CI) of the PFS, OS, ORR and safety outcomes were obtained using either a fixed-effects model or in the event of heterogeneity, a random-effects model. Relative risks (RRs) and 95% CIs were calculated to assess the ORR and safety of BV compared with control group. Subgroup analyses to identify the overall impact of patient and trial characteristics on BV efficacy were performed for the following characteristics: different tumor types, BV dose (high-dose (5 mg/kg weekly) and low-dose (2.5 mg/kg weekly)), types of adjuvant therapies (platinum (cisplatin, carboplatin, or oxaliplatin) and taxanes (paclitaxel or docetaxel) versus non-platinum (non-platinum and nontaxane-based)), age of participants (50--55, 56--60, 61--66, \>66 years old), median duration of follow-up (6--12, 13--24, 25--36, \>37 months), median duration of BV therapy (\<12, 12--24, 25--36, \>37 weeks) and timing of response assessment (6, 8--12, 24 weeks). These subgroup analyses were performed for all trials combined, colorectal cancer, non-small cell lung cancer (NSCLC) and breast cancer patients separately. The time interval between mOS and mPFS was measured as survival post progression (SPP) in different tumor types including colorectal cancer, NSCLC, breast cancer and ovarian cancer. The validation of PFS as a surrogate endpoint for OS in all combined trials was tested using the Spearman's rank correlation. Linearity between the log HRs of PFS and OS was also assessed in a linear regression model. The correlation between PFS and OS was further studied in subgroup analyses in different tumor types including colorectal cancer, NSCLC and breast cancer. Publication bias was evaluated by using funnel plots and the Egger test was applied to measure any asymmetry. Heterogeneity of the studies was tested by the I^2^ measure of inconsistency with 25% corresponding to low heterogeneity, 50% to moderate and 75% to high. If heterogeneities existed, one of the following techniques was used to explain them: random-effects models for meta-analysis, subgroup analyses, or meta-regression analyses. Meta-regression analyses were also performed for the BV dose, median age of participants, median duration of follow-up and median duration of BV therapy. To evaluate the relation between BV doses and the risk of ADRs a subgroup analysis was performed. In addition, sensitivity analysis was applied by omitting one study in each turn and investigated the influence of a single study on the overall meta-analysis estimate \[[@pone.0136324.ref007]\] when necessary. All statistical analyses were conducted using STATA 10/SE (StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP).

Results {#sec011}
=======

Search results {#sec012}
--------------

**[Fig 1](#pone.0136324.g001){ref-type="fig"}** shows a flow chart for the selection procedure of the trials. Our literature search yielded 1,465 published articles on BV safety and efficacy and after applying the inclusion and exclusion criteria a total of 44 RCTs \[[@pone.0136324.ref008]--[@pone.0136324.ref011],[@pone.0136324.ref011]--[@pone.0136324.ref019],[@pone.0136324.ref019]--[@pone.0136324.ref028],[@pone.0136324.ref029]--[@pone.0136324.ref051]\] were selected for the meta-analyses **([Fig 1](#pone.0136324.g001){ref-type="fig"})**.

![A Flow Diagram showing the RCTs selection.](pone.0136324.g001){#pone.0136324.g001}

Study characteristics {#sec013}
---------------------

The characteristics of the included trials are summarized in **[Table 1](#pone.0136324.t001){ref-type="table"}**. A total of 30,828 patients (BV, n = 16,266; control, n = 14,562) from 44 RCTs were included in the meta-analysis. Underlying malignancies were included colorectal cancer (13 studies), breast cancer (10 studies), NSCLC (7 studies), ovarian cancer (4 studies), renal cell cancer (2 studies), pancreatic cancer (2 studies), gastric cancer (1 study), melanoma cancer (1 study), prostate cancer (1 study), mesothelioma cancer (1 study), cervical cancer (1 study) and Follicular lymphoma (1 study). Five trials evaluated BV in different arms, either different doses of BV \[[@pone.0136324.ref014],[@pone.0136324.ref026],[@pone.0136324.ref027],[@pone.0136324.ref035]\] or its combination with different adjuvant therapy agents \[[@pone.0136324.ref034]\] with a control group. Sample sizes ranged from 23 to 2,867 patients, with 24 trials including more than 500 patients each. In all trials, patients were randomly assigned to either the control or the BV group. Eleven (25%) trials were phase II and 33 (75%) were phase III studies. Trial treatment regimens varied by tumor types and the BV dose ranged from 2.5 to 5 mg/kg weekly. The median age of patients in all trials combined was almost 59 years in both groups. All studies recruited both male and female participants (except trials of metastatic breast cancer, ovarian cancer, prostate cancer and cervical cancer) however outcomes were not reported stratified by gender.

10.1371/journal.pone.0136324.t001

###### Characteristics of trials included in the meta-analysis.

![](pone.0136324.t001){#pone.0136324.t001g}

  RCTs                               Tumor type   Allocation sequences   Trial phase   Enrolled patients   Adjuvant therapy                                      BV dose, mg/kg/week   Median duration of follow--up (months)   Time points of response assessment (weeks)
  ---------------------------------- ------------ ---------------------- ------------- ------------------- ----------------------------------------------------- --------------------- ---------------------------------------- --------------------------------------------
  **Bennouna, J et al, 2013**        MCRC         C                      III           820                 Oxaliplatin plus Irrinotecan                          2.5                   11.1                                      NA
  **Cunnigham, D et al, 2013**       MCRC         C                      III           280                 Capecitabine                                          2.5                   24.8                                     9
  **De Gramont, A et al, 2012**      MCRC         C                      III           2867                Oxaliplatin, fluorouracil, and leucovorin (FOLFOX4)   2.5                   48                                       24
  **Dotan, E et al, 2012**           MCRC         C                      II            23                  Capecitabine plus Oxaliplatin plus Cetuximab          2.5                   25.9                                     6
  **Kemeny, NE et al, 2011**         MCRC         C                      II            73                   Oxaliplatine plus Fluorouracil plus Leucovorin       2.5                   30                                       NA
  **Guan, ZZ et al, 2011**           MCRC         C                      III           214                 Irinotecan plus leucovorin, and 5-fluorouracil        2.5                   NA                                       6
  **Allegra,C J et al, 2011**        MCRC         C                      III           2710                FOLFOX6                                               2.5                   35.6                                     NA
  **Tebbutt, N et al, 2009**         MCRC         C                      III           471                 Capecitabine                                          2.5                   31                                       6
  **Stathopulos, GP et al, 2010**    MCRC         C                      III           222                 leucovorin plus 5-fluorouracil plus irinotecan        2.5                   36                                       8
  **Saltz, LB et al, 2008**          MCRC         B                      III           1401                FOLFOX-4 / XELOX                                      2.5                   27.6                                     6
  **Giantanio, BJ et al, 2007**      MCRC         C                      III           829                 FOLFOX4                                               5                     28                                       12
  **Hurwitz, HI et al, 2004**        MCRC         B                      III           813                 Irinotecan plus fluorouracil, and leucovorin          2.5                   18                                       6
  **Kabbinavar, F et al, 2003**      MCRC         C                      II            104                 Fluorouracil l/ leucovorin                            2.5, 5                17.6                                     8
  **Cameron, D et al, 2013**         MBC          C                      III           2591                Antracycline plus Taxane                              5                     31.5                                     NA
  **Luca, G et al, 2013**            MBC          C                      III           424                 Docetaxel plus Trastuzumab                            5                     26                                       9
  **Von Minckwitz, G et al, 2012**   MBC          C                      III           1948                Epirubicin plus cyclophosphamide plus docetaxel       5                     NA                                       6
  **Bear, H et al, 2012**            MBC          C                      III           1206                Docetaxel plus Capecitabine                           5                     NA                                       NA
  **Brufsky, AM et al, 2011**        MBC          A                      III           684                 Capecitabine plusa Taxane                             5                     15                                       6
  **Robert, NJ et al, 2011**         MBC          A                      III           618                 Capecitabine plus Taxane--based                       5                     15.6, 19.2                               9
  **Martin, M et al, 2011**          MBC          A                      II            191                 Paclitaxel                                            2.5                   NA                                       8
  **Miles, DW et al, 2010**          MBC          A                      III           736                 Docetaxel                                             2.5, 5                25                                       9
  **Miller, K et al, 2007**          MBC          C                      III           722                 Paclitaxel                                            5                     41.6                                     12
  **Miller, KD et al, 2005**         MBC          C                      III           462                 Capecitabine                                          5                     14.8                                     6
  **Niho, S et al, 2012**            NSCLC        C                      II            180                 Carboplatin plus Paclitaxel                           5                     NA                                       6
  **Herbst, RS et al, 2011**         NSCLC        C                      III           636                 Erlotinib                                             5                     19                                       6
  **Spigel, DR et al, 2011**         NSCLC        A                      II            102                 Cisplatin or Carboplatin plus Etoposide               5                     7.8                                      6
  **Reck, M et al, 2009**            NSCLC        B                      III           1043                Cisplatin plus Gemcitabine                            2.5, 5                7                                        9
  **Herbst,R et al, 2007**           NSCLC        C                      II            120                 Docetaxel or Pemetrexed                               5                     15.8                                     6
  **Sandler, A et al, 2006**         NSCLC        C                      III           878                 Paclitaxel plus Carboplatin                           5                     19                                       6
  **Johnson, DH et al, 2004**        NSCLC        C                      II            99                  Carboplatin plus Paclitaxel                           2.5, 5                14.7                                     6
  **Eric, PL et al, 2014**           OC           C                      III           361                 Doxorubicin plus Paclitaxel plus Topotecan            5                     13.9                                     8
  **Aghajanian, C et al, 2012**      OC           A                      III           484                 Carboplatin plus Gemcitabine                          5                     24                                       9
  **Perren,T et al, 2011**           OC           C                      III           1528                Carboplatin plus Paclitaxel                           2.5                   28                                       6
  **Burger, RA et al, 2011**         OC           A                      III           1873                Paclitaxel plus Carboplatin                           5                     17.4                                     NA
  **Kindler, HL et al, 2010**        MPC          A                      III           602                 Gemcitabine                                           2.5                   11.3                                     6
  **Cutsem, E et al, 2009**          MPC          A                      III           607                 Gemcitabine plus Erlotinib                            2.5                   6.7                                      8
  **Rini, BI et al, 2010**           RCC          C                      III           732                 Interferon alpha                                      5                     46.2                                     12
  **Escudier, B et al, 2007**        RCC          A                      III           649                 Interferon alfa-2a                                    5                     13.3                                     8
  **Krishnansu, ST et al, 2014**     CC           C                      III           452                 Cisplatin plus Paclitaxel                             5                     20.8                                     NA
  **John, DH et al, 2014**           RFL          C                      II            60                  Rituximab                                             5                     34                                       NA
  **Kim, KB et al, 2012**            MC           A                      II            214                 Carboplatin plus paclitaxel                           5                     13                                       6
  **Kelly, WK et al, 2012**          PC           A                      III           1050                Docetaxel plus prednisone                             5                     24                                       12
  **Kindler, HL et al, 2012**        AM           A                      II            115                 Gemcitabine plus Cisplatin                            5                     NA                                       6
  **Ohtsu, A et al, 2011**           GC           A                      III           774                 Cisplatin plus Capecitabine                           2.5                   11.4                                     6

**Abbreviations:** RCTs: randomized control trials; BV: bevacizumab; MCRC: metastatic colorectal cancer; GC: gastric cancer; MPC: metastatic pancreatic cancer; RCC: renal carcinoma cancer; NSCLC: non-small-cell lung carcinoma; MBC: metastatic breast cancer; AM: advanced mesothelioma; PC: prostate cancer; MC: melanoma carcinoma; OC: ovarian cancer; CC: cervical cancer; RFL: Relapsed Follicular Lymphoma, A: Double-blinded- placebo and active treatment control, B: Placebo and active treatment control, C: Active treatment control.

Risk of bias assessment in all trials combined {#sec014}
----------------------------------------------

Randomized treatment allocation sequences were generated in 44 RCTs. Fourteen trials were double blinded with placebo and active treatment controls, 3 trials had placebo and active treatment controls and the rest of trials had active treatment controls. **[S2 Table](#pone.0136324.s006){ref-type="supplementary-material"}** presents the risk of bias judgments for the 44 RCTs. According to our methodological assessment, the results showed a low risk of bias in most domains except for blinding across all outcomes; therefore, the overall quality of all trials combined was acceptable.

Efficacy analyses in all trials combined {#sec015}
----------------------------------------

The meta-analysis of PFS was based on 38 RCTs (**[Table 2](#pone.0136324.t002){ref-type="table"}**). Combining BV with different adjuvant therapies resulted in a 13% risk reduction of PFS events (log HR, 0.87; 95% CI, 0.84--0.89; I^2^:72.4%, random-effects model) (**[Fig 2](#pone.0136324.g002){ref-type="fig"}**) with high heterogeneity attributed to the colorectal cancer (I^2^: 82.3%) and ovarian cancer (I^2^: 92.8%) trials. PFS statistically significantly improved in patients for all types of tumors except for patients with melanoma, mesothelioma and cervical cancers. No statistically significant differences between logs HRs of PFS were observed between the different tumor types.

![Meta-analysis of the log hazard ratios of progression free survival comparing bevacizumab and standard therapy in all trials combined.](pone.0136324.g002){#pone.0136324.g002}

10.1371/journal.pone.0136324.t002

###### BV efficacy assessment in trials included in the meta-analysis.

![](pone.0136324.t002){#pone.0136324.t002g}

                           PFS      OS                ORR                                                                                                                                                                                     
  ------------------------ -------- ----------------- ----------------- ------------------- ------ -------- ----------------- ----------------- ------------------- ------ -------- ---------------- ---------------- ----------------------- ----------
  **All trial combined**   **38**   **12221/24696**   **10756/24696**   0.87 (0.84--0.89)   72.4   **34**   **11611/23821**   **10491/23821**   0.96 (0.94--0.98)   22.2   **24**   **7898/14596**   **6385/14596**   **1.46 (1.33--1.59)**   **71.3**
  Colorectal cancer        10       3364/7681         3346/7681         0.85 (0.79--0.92)   82.3   9        3224/7401         3206/7401         0.93 (0.87--0.99)   61.1   6        1606/3384        1514/3384        1.40 (1.01--1.95)       84.2
  NSCLC                    7        1712/3058         1279/3058         0.85 (0.82--0.89)   13.0   6        1016/2015         932/2015          0.94 (0.90--0.98)   0      4        1188/1961        773/1961         1.60 (1.37--1.87)       9.4
  Breast cancer            7        2670/4456         1737/4456         0.87 (0.84--0.91)   50.5   6        3658/6432         2725/6432         0.98 (0.94--1.01)   0      6        2454/4032        1529/4032        1.36 (1.25--1.47)       10.4
  Pancreatic cancer        2        608/1209          601/1209          0.90 (0.85--0.96)   36.5   2        608/1209          601/1209          1.01 (0.94--1.08)   0      2        608/1209         601/1209         1.41 (1.02--1.95)       0
  Ovarian cancer           4        2035/4698         2038/4698         0.86 (0.76--0.99)   92.8   3        1044/2718         1049/2718         0.97 (0.91--1.03)   0      3        1185/2373        1188/2373        1.47 (1.25--1.73)       68.7
  Renal Cancer             2        696/1381          685/1381          0.84 (0.80--0.89)   0      2        696/1381          685/1381          0.95 (0.90--0.99)   0      1        1016/2015        932/2015         **2.55 (1.81--3.61)**   **-**
  Gastric Cancer           1        387/774           387/774           0.91 (0.85--0.97)   \-     1        387/774           387/774           0.94 (0.87--1.01)   \-     1        387/774          387/774          1.29 (1.05--1.58)       \-
  Prostate Cancer          1        524/1050          526/1050          0.91 (0.86--0.96)   \-     1        524/1050          526/1050          0.96 (0.90--1.02)   \-     \-       \-               \-               \-                      \-
  Melanoma Cancer          1        143/214           71/214            0.90 (0.78--1.04)   \-     1        143/214           71/214            0.84 (0.71--0.99)   \-     1        143/214          71/214           1.49 (0.83--2.68)       \-
  Mesothelioma Cancer      1        53/115            55/115            0.96 (0.79--1.15)   \-     1        53/115            55/115            1.02 (0.85--1.22)   \-     \-       \-               \-               \-                      \-
  Cervical cancer          1        227/452           225/452           1.15 (1.04--1.28)   \-     1        227/452           225/452           1.08 (0.92--1.28)   \-     \-       \-               \-               \-                      \-
  Lymphoma                 1        29/60             31/60             0.67 (0.50--0.91)   \-     1        29/60             31/60             0.67 (0.44--1.02)   \-     \-       \-               \-               \-                      \-

**Abbreviations:** PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab; NSCLC: non-small cell lung cancer.

The meta-analysis of OS was based on 34 RCTs. Adding BV caused a 4% risk reduction of OS events as compared with regimens without BV (log HR, 0.96; 95% CI, 0.94--0.98; I^2^:22.2%, fixed-effects model) (**[Fig 3](#pone.0136324.g003){ref-type="fig"}**). When investigating by type of tumor, OS was significantly improved only in colorectal cancer, NSCLC, renal cancer and melanoma cancer. Again the results showed no significant difference between logs HRs of OS in different tumor types.

![Meta-analysis of the logs hazard ratios of overall survival comparing bevacizumab and standard therapy in all trials combined.](pone.0136324.g003){#pone.0136324.g003}

The meta-analyzed RR of the ORR associated with the addition of BV to adjuvant therapy in 24 studies was 1.46 (95% CI: 1.33--1.59; I^2^: 71.3%, random-effects model) (**[Fig 4](#pone.0136324.g004){ref-type="fig"}**). High heterogeneity was observed in the colorectal cancer (I^2^: 84.2%) trials. The ORR was statistically significantly improved in all tumor types except in patients with melanoma cancer. Furthermore, the highest improvement of ORR was observed among renal cancer patients (RR, 2.55; 95% CI, 1.81--3.61). This was statistically significant different from the other tumor types.

![Meta-analysis of the risk ratios of overall response rate comparing bevacizumab and standard therapy in all trials combined.](pone.0136324.g004){#pone.0136324.g004}

Efficacy subgroup analyses {#sec016}
--------------------------

As shown in Tables [3](#pone.0136324.t003){ref-type="table"} and [4](#pone.0136324.t004){ref-type="table"}, patient and trial characteristics did not modify the effects of BV on PFS and OS. For specific tumor types including colorectal cancer, NSCLC and breast cancer, the overall pooled estimates of logs HRs of PFS (Figures A, B and C in **[S1 File](#pone.0136324.s002){ref-type="supplementary-material"}**) and OS (Figures A, B and C in **[S2 File](#pone.0136324.s003){ref-type="supplementary-material"}**) and RRs of ORR (Figures A, B and C in **[S3 File](#pone.0136324.s004){ref-type="supplementary-material"}**) comparing BV and standard chemotherapy are shown in forest plots.

10.1371/journal.pone.0136324.t003

###### Efficacy subgroup analyses in all trials combined.
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                                                   PFS   OS                  ORR                                                                 
  ------------------------------------------------ ----- ------------------- ------ ---- ------------------- ------ ---- ----------------------- ------
  **BV dose**                                                                                                                                    
  2.5 mg/kg                                        17    0.88 (0.84--0.92)   72.3   13   0.96 (0.92--1.01)   50.4   11   1.26 (1.09--1.45)       74.6
  5 mg/kg                                          25    0.86 (0.83--0.89)   71.6   24   0.95 (0.93--0.97)   0      15   1.58 (1.43--1.74)       \-
  **Chemotherapy regimen**                                                                                                                       
  Platinum                                         30    0.88 (0.85--0.91)   74.5   25   0.96 (0.93--0.98)   27.5   17   1.40 (1.26--1.56)       77.0
  Non-platinum                                     13    0.84 (0.80--0.88)   62.6   11   0.96 (0.93--1.00)   13.7   10   1.58 (1.36--1.84)       43.6
  **Age (years)**                                                                                                                                
  50--55                                           8     0.88 (0.83--0.93)   55.6   6    0.98 (0.93--1.03)   0      7    1.32 (1.20--1.44)       0
  56--60                                           14    0.87 (0.83--0.92)   80.5   11   0.96 (0.92--1.01)   52.4   12   1.34 (1.18--1.52)       77.9
  61--65                                           10    0.84 (0.80--0.88)   58.2   10   0.95 (0.92--0.98)   15.9   7    **2.04 (1.67--2.49)**   33.1
  \>66                                             3     0.84 (0.75--0.95)   68.9   3    0.94 (0.87--1.02)   25.6   \-                           
  **Median Follow-up (months)**                                                                                                                  
  6--12                                            6     0.88 (0.85--0.92)   26.1   5    0.96 (0.91--1.01)   26.5   5    1.40 (1.22--1.60)       0
  13--24                                           18    0.84 (0.80--0.89)   79.7   17   0.95 (0.93--0.98)   7.6    11   1.52 (1.35--1.72)       53.8
  25--36                                           9     0.88 (0.84--0.92)   47.5   8    0.93 (0.88--0.99)   37.7   6    1.32 (1.03--1.69)       90.4
  \>37                                             3     0.90 (0.77--1.07)   93.9   3    0.99 (0.90--1.09)   78.9   \-   \-                      \-
  **Median duration of therapy (weeks)**                                                                                                         
  \<12                                             \-    \-                  \-     \-   \-                  \-     \-   \-                      \-
  12--24                                           10    0.85 (0.79--0.92)   83.1   9    0.97 (0.91--1.03)   62.2   7    1.74 (1.41--2.16)       50.7
  25--36                                           10    0.84 (0.80--0.89)   70.0   8    0.96 (0.92--0.98)   0      8    1.35 (1.14--1.60)       79.9
  \>37                                             4     0.83 (0.76--0.90)   61.1   3    0.91 (0.83--1.00)   23.3   2    1.78 (0.90--3.53)       92.0
  **Time points of response assessment (weeks)**                                                                                                 
  6                                                17    0.87 (0.84--0.91)   55.7   16   0.95 (0.92--0.98)   22.9   13   1.34 (1.16--1.54)       74.1
  8--12                                            16    0.83 (0.80--0.87)   66.0   12   0.94 (0.92--0.97)   0      11   1.68 (1.41--1.99)       74.2
  24                                               1     1.07 (0.99--1.16)   \-     1    1.11 (1.01--1.22)   \-     \-   \-                      \-

**Abbreviations:** PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab.

10.1371/journal.pone.0136324.t004

###### Efficacy subgroup analyses in different tumor types.
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                                                   PFS     OS                  ORR                                                                       
  ------------------------------------------------ ------- ------------------- ------ ------- ------------------- ------ ------- ----------------------- -------
  **Metastatic Colorectal Cancer**                                                                                                                       
  **BV dose**                                                                                                                                            
  2.5 mg/kg                                        9       0.86 (0.79--0.94)   84.8   8       0.94 (0.87--1.01)   65.1   5       1.22 (0.89--1.67)       80.4
  5 mg/kg                                          2       0.81 (0.75--0.87)   0      2       0.89 (0.82--0.95)   0      2       2.15 (1.15--3.99)       40.7
  **Chemotherapy regimen**                                                                                                                               
  Platinum                                         6       0.91 (0.83--1.01)   84.7   6       0.95 (0.87--1.04)   75.1   3       1.12 (0.49--2.55)       91.6
  Non-platinum                                     4       0.78 (0.74--0.82)   0      3       0.90 (0.83--0.98)   0      4       1.51 (1.12--2.04)       28.0
  **Age (years)**                                                                                                                                        
  50--55                                           1       0.76 (0.68--0.85)   0      \-      \-                  \-     1       2.05 (1.14--3.67)       \-
  56--60                                           4       0.91 (0.78--1.07)   91.2   4       0.94 (0.81--1.08)   80.5   3       1.02 (0.80--1.38)       82.3
  61--65                                           2       0.83 (0.79--0.87)   0      2       0.90 (0.86--0.94)   0      1       **2.64 (1.72--4.07)**   \-
  \>66                                             1       0.82 (0.74--0.90)   0      1       0.95 (0.85--1.06)   \-     \-      \-                      \-
  **Median Follow-up (months)**                                                                                                                          
  6--12                                            1       0.85 (0.80--0.90)   0      1       0.91 (0.85--0.98)   \-     \-      \-                      \-
  13--24                                           3       0.76 (0.71--0.81)   0      2       0.83 (0.72--0.96)   0      2       1.53 (0.88--2.65)       51.5
  25--36                                           5       0.86 (0.80--0.94)   58.6   5       0.92 (0.86--0.98)   35.1   3       1.12 (0.49--2.55)       91.6
  \>37                                             1       1.07 (0.99--1.16)   \-     1       1.11 (1.01--1.22)   0      \-      \-                      \-
  **Median duration of therapy (weeks)**                                                                                                                 
  \<12                                             \-      \-                  \-     ---     \-                  \-     \-      \-                      \-
  12--24                                           2       0.93 (0.70--1.23)   96.2   2       0.99 (0.79--1.24)   93.0   1       **2.64 (1.72--4.07)**   \-
  25--36                                           3       0.84 (0.74--0.94)   81.3   2       0.95 (0.90--1.00)   0      2       1.33 (0.63--2.79)       84.4
  \>37                                             1       0.76 (0.70--0.83)   \-     1       0.84 (0.71--0.99)   \-     1       1.29 (1.08--1.53)       \-
  **Time points of response assessment (weeks)**                                                                                                         
  6                                                4       0.84 (0.75--0.94)   78.3   4       0.91 (0.83--1.00)   43.5   4       1.13 (0.82--1.54)       81.9
  8--12                                            3       0.79 (0.74--0.84)   0      2       0.88 (0.82--0.94)   0      2       **2.59 (1.77--3.80)**   0
  24                                               1       1.07 (0.99--1.16)   \-     1       1.11 (1.01--1.22)   \-     \-      \-                      \-
  **Metastatic NSCLC**                                                                                                                                   
  **BV dose**                                                                                                                                            
  2.5 mg/kg                                        2       0.87 (0.80--0.94)   0      1       0.90 (0.69--1.18)   \-     \-      \-                      \-
  5 mg/kg                                          7       0.85 (0.81--0.89)   25.3   6       0.94 (0.90--0.99)   0      5       1.60 (1.37--87)         9.4
  **Chemotherapy regimen**                                                                                                                               
  Platinum                                         8       0.86) 0.83--0.90)   5.3    6       0.92 (0.87--0.97)   0      3       1.57 (1.32--1.86)       18.6
  Non-platinum                                     1       0.81 (0.75--0.88)   0      1       0.99 (0.91--1.07)   \-     1       1.99 (1.17--3.37)       \-
  **Age (years)**                                                                                                                                        
  50--55                                           \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  56--60                                           3       0.89 (0.83--0.95)   20.3   1       1.07 (0.83--1.36)   \-     3       1.51 (1.26--1.80)       12.8
  61--65                                           3       0.81 (0.75--0.87)   0      3       0.98 (0.91--1.05)   0      2       1.98 (1.43--2.74)       0
  \>66                                             \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  **Median Follow-up (months)**                                                                                                                          
  6--12                                            2       0.85 (0.74--0.97)   39.3   1       1.07 (0.83--1.36)   \-     2       1.47 (1.04--2.06)       57.2
  13--24                                           4       0.82 (0.79--0.86)   0      4       0.93 (0.88--0.98)   2.3    1       1.99 (1.17--3.37)       \-
  25--36                                           \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  \>37                                             \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  **Median duration of therapy (weeks)**                                                                                                                 
  \<12                                             \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  12--24                                           5       0.84 (0.80--0.88)   0      4       0.92 (0.87--0.98)   0      3       1.59 (1.22--2.07)       44.4
  25--36                                           \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  \>37                                             1       0.83 (0.65--1.06)   \-     1       0.86 (0.68--1.09)   \-     \-      \-                      \-
  **Time points of response assessment (weeks)**                                                                                                         
  6                                                6       0.82 (0.78--0.86)   0      6       0.94 (0.90--0.99)   0      3       1.64 (1.14--2.35)       52.6
  8--12                                            1       0.88 (0.81--0.96)   \-     \-      \-                  \-     1       1.69 (1.31--2.19)       \-
  24                                               \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  **Metastatic Breast Cancer**                                                                                                                           
  **BV dose**                                                                                                                                            
  2.5 mg/kg                                        2       0.91 (0.83--0.98)   0      1       1.02 (0.91--1.14)   \-     2       1.18 (1.01--1.37)       0
  5 mg/kg                                          6       0.87 (0.82--0.92)   59.8   6       0.97 (0.93--1.01)   0      7       1.42 (1.30--1.55)       0
  **Chemotherapy regimen**                                                                                                                               
  Platinum                                         6       0.86 (0.82--0.90)   36.6   6       0.97 (0.93--1.01)   0      5       1.34 (1.20--1.49)       32.0
  Non-platinum                                     2       0.92 (0.79--1.06)   78.9   2       0.99 (0.88--1.12)   47.5   2       1.43 (1.21--1.68)       0
  **Age (years)**                                                                                                                                        
  50--55                                           7       0.89 (0.85--0.93)   31.0   5       0.98 (0.93--1.03)   0      4       1.31 (1.19--1.44)       0
  56--60                                           2       0.82 (0.77--0.87    11.8   2       0.96 (0.90--1.03)   0      3       1.51 (1.24--1.85)       29.5
  61--65                                           \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  \>66                                             \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  **Median Follow-up (months)**                                                                                                                          
  6--12                                            \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  13--24                                           3       0.89 (0.82--0.95)   60.4   3       1.07 (0.83--1.36)   0      3       1.38 (1.22--1.55)       0
  25--36                                           2       0.91 (0.85--0.98)   0      2       0.97 (0.93--1.00)   2.3    2       1.41 (0.93--2.12)       86.1
  \>37                                             1       0.80 (0.75--0.86)   \-     1       0.93 (0.88--0.98)   \-     \-      \-                      \-
  **Median duration of therapy (weeks)**                                                                                                                 
  \<12                                             **-**   \-                  \-     **-**   \-                  \-     **-**   **-**                   **-**
  12--24                                           \-      \-                  \-     \-      \-                  \-     \-      \-                      \-
  25--36                                           4       0.85 (0.80--0.90)   40.5   3       0.92 (0.87--0.98)   0      4       1.46 (1.25--1.71)       15.9
  \>37                                             1       0.92 (0.83--1.01)   0      \-      \-                  \-     \-      \-                      \-
  **Time points of response assessment (weeks)**                                                                                                         
  6                                                2       0.94 (0.85--1.03)   53.2   2       0.99 (0.84--1.47)   28.9   2       1.42 (1.15--1.75)       0
  8--12                                            5       0.87 (0.82--0.92)   45.9   3       0.94 (0.90--0.99)   0      4       1.38 (1.12--1.71)       62.9
  24                                               \-      \-                  \-     \-      \-                  \-     \-      \-                      \-

**Abbreviations:** PFS: progression free survival; OS: overall survival; ORR: overall response rate; HR: hazard ratio; RR: relative risk; BV: bevacizumab; NSCLC: non-small cell lung cancer.

A statistically significant improvement in ORR was found for 61--65 years old patients compared to the other age groups in all trials combined (RR: 2.04, 95% CI: 1.67--2.49) and in the colorectal cancer trials (RR: 2.64, 95% CI: 1.72--4.07). The highest ORR was observed in studies with a median duration of therapy between 12--24 weeks for colorectal cancer (RR: 2.64, 95% CI: 1.72--4.07). The ORR was higher in colorectal cancer studies if the response was assessed between 8--12 weeks compared to 6 weeks (RR: 2.59, 95% CI: 1.77--3.80 vs. RR: 1.13, 95% CI: 0.82--1.54). For the other subgroup analyses, RR of ORR did not statistically significantly differ.

Survival post progression {#sec017}
-------------------------

SPP calculated in 7 colorectal cancer trials was 10.6 months. In NSCLC (6 studies), breast cancer (4 studies) and ovarian cancer (3 studies) SPP times were 9.2, 15.6 and 21.1 months, respectively.

Evaluating the relationship between PFS and OS {#sec018}
----------------------------------------------

The results showed a significant moderate association between PFS and OS across all combined trials (The Spearman correlation coefficient (r) was 0.41, p-value: 0.01) (**[Fig 5](#pone.0136324.g005){ref-type="fig"}**).

![Spearman's correlation between progression free survival and overall survival.](pone.0136324.g005){#pone.0136324.g005}

Results of subgroup analyses showed that the correlation between PFS and OS was stronger in studies of metastatic breast cancers (r: 0.57; p-value: 0.18) compared to metastatic colorectal cancer (r: 0.40; p-value: 0.24) and NSCLC (r:-0.45; p-value: 0.31).

Publication bias {#sec019}
----------------

The funnel plots did not show evidence of significant publication bias for PFS and OS (p-values: 0.42, 0.69, respectively). However for ORR, the funnel plot appeared to be asymmetric, and there was evidence of bias using the Egger (weighted regression) method (P for bias was 0.02). It appeared that small trials producing more pronounced effects were missing **([Fig 6](#pone.0136324.g006){ref-type="fig"})**.

![Funnel plots for efficacy assessment in all trials combined.](pone.0136324.g006){#pone.0136324.g006}

Heterogeneity {#sec020}
-------------

Moderate heterogeneity was observed for PFS (I^2^: 72.4%) and for ORR (I^2^: 71.3%) in all combined trials **([Table 2](#pone.0136324.t002){ref-type="table"})**. We further explored the causes of the heterogeneity in different tumor types. PFS and ORR were more heterogeneous when analyzed separately in colorectal cancer trials (I^2^: 82.3% and 84.2%, respectively). Other stratified subgroup analyses were performed and indicated the large differences in the HRs of PFS and RRs of ORR across BV dose and adjuvant therapy agents in colorectal cancer trials **(Tables [3](#pone.0136324.t003){ref-type="table"}&[4](#pone.0136324.t004){ref-type="table"})**.

Meta-regression analysis {#sec021}
------------------------

The potential influence of patient and trial characteristics including BV dose, participant's age, median duration of follow-up and median duration of BV therapy on study outcomes was explored in meta-regression analyses. The analyses showed that none of these characteristics statistically significantly influenced PFS and OS in all trials combined. However BV dose was found to be a predictor of ORR benefit (p-value: 0.02) (**[Table 5](#pone.0136324.t005){ref-type="table"}**).

10.1371/journal.pone.0136324.t005

###### Meta-regression analyses.

![](pone.0136324.t005){#pone.0136324.t005g}

            Predictors p-value                 
  --------- -------------------- ------ ------ ------
  **PFS**   0.48                 0.05   0.53   0.87
  **OS**    0.33                 0.18   0.71   0.15
  **ORR**   **0.02**             0.20   0.48   1.00

**Abbreviations:** PFS: progression free survival; OS: overall survival; ORR: overall response rate; BV: bevacizumab.

ADRs analyses {#sec022}
-------------

ADRs data was available on all grades and on those ADRs with grade 3 (severe) or more (life threatening). ADRs were reported differently among 44 RCTs **([Table 6](#pone.0136324.t006){ref-type="table"})**. BV was associated with a higher risk of all grade ADRs e.g. thrombocytopenia, hypertension, bleeding and thromboembolic events. A higher risk of severe grade events such as wound healing complication, epistaxis and stomatitis was also observed in patients treated by BV. The highest risk was found for severe grade hypertension (RR: 5.83, 95% CI: 4.44--7.65) which was reported in 40 trials where 1,149 patients out of 16,437 in the BV treated group and 147 patients out of 15,378 in the control group were diagnosed with this ADR. BV significantly reduced the risk of both all grade (RR: 0.83, 95% CI: 0.71--0.98) and severe grade (RR: 0.78, 95% CI: 0.66--0.93) anemia as well as severe grade fatigue (RR: 0.58, 95% CI: 0.38--0.87) compared with adjuvant therapy alone in cancer patients. No statistically significant differences between patients with and without BV in their regime were found for venous thromboembolic events, fistula abdominal abscess, leukopenia, cardiac events including left ventricular (LV) dysfunction and congestive heart failure and pulmonary events including embolism, dyspnea, pneumonitis and hemorrhages.

10.1371/journal.pone.0136324.t006

###### Safety assessment of ADRs with BV in all trials combined.

![](pone.0136324.t006){#pone.0136324.t006g}

                                                                 All grade   Severe grade                                                                   
  -------------------------------------------------------------- ----------- -------------- ----------- -------------------- ---- ------------ ------------ --------------------
  **Venous Thromboembolic Events**                               6           156/10621      127/9977    1.16 (0.82--1.64)    19   507/10621    410/9977     1.18 (0.98--1.43)
  **Thrombocytopenia**                                           8           192/6755       148/6537    1.23 (1.01--1.49)    21   365/6755     323/6537     1.13 (0.89--1.44)
  **Anemia**                                                     5           221/6955       257/6744    0.83 (0.71--0.98)    17   236/6955     295/6744     0.78 (0.66--0.93)
  **Hypertension**                                               13          723/16437      190/15378   3.46 (2.72--4.41)    40   1149/16437   147/15378    5.83 (4.44--7.65)
  **Bleeding**                                                   7           310/14173      114/13269   2.71 (1.80--4.09)    30   276/14173    139/13269    1.84 (1.43--2.35)
  **Thromboembolic Events**                                      4           113/4560       82/4486     1.35 (1.04--1.76)    11   161/4560     96/4486      1.81 (1.10--2.97)
  **Arterial Thromboembolic Events**                             7           48/7775        24/7162     1.49 (0.90--2.45)    14   99/7775      51/7162      1.68 (1.13--2.50)
  **Gastrointestinal perforation**                               7           41/11677       16/11094    1.97 (1.07--3.64)    23   201/11677    124/11094    2.06 (1.27--3.34)
  **Wound Healing Complication**                                 3           13/7312        6/7155      1.90 (0.74--4.88)    12   51/7312      21/7155      1.94 (1.08--3.49)
  **Fistula Abdominal Abscess**                                  3           9/5199         1/5092      4.51 (0.97--20.91)   8    38/5199      21/5092      1.51 (0.51--4.42)
  **Neutropenia**                                                8           339/13519      259/12492   1.20 (1.05--1.37)    32   3913/13519   3606/12492   1.06 (1.01--1.12)
  **Febrile Neutropenia**                                        5           189/9940       104/9208    1.55 (1.09--2.19)    20   383/9940     247/9208     1.42 (1.22--1.66)
  **Leukopenia**                                                 4           84/3810        65/3692     1.26 (0.94--1.68)    10   411/3810     183/3692     1.52 (0.98--2.36)
  **Proteinuria**                                                8           524/13562      142/12621   4.98 (2.11--11.71)   30   299/13562    36/12621     4.90 (3.53--6.80)
  **Diarrhea**                                                   12          533/7807       476/7600    1.09 (0.97--1.22)    23   683/7807     533/7600     1.21 (1.07--1.37)
  **Epistaxis**                                                  4           154/977        46/989      3.23 (2.38--4.38)    6    14/977       3/989        3.84 (1.29--11.37)
  **Stomatitis**                                                 4           133/2910       69/2742     1.87 (1.45--2.39)    6    97/2910      28/2742      3.25 (2.14--4.93)
  **Vomiting**                                                   7           28/6787        16/6540     1.04 (0.87--1.24)    17   3/6787       2/6540       1.33 (1.00--1.76)
  **Nausea**                                                     8           579/6703       561/6502    1.02 (0.93--1.11)    18   225/6703     151/6502     1.42 (1.13--1.78)
  **Fatigue**                                                    7           766/6518       727/6329    1.01 (0.93--1.10)    7    566/6518     413/6329     0.58 (0.38--0.87)
  **Rash**                                                       4           196/1815       157/1823    1.50 (0.93--2.43)    6    87/1815      33/1823      2.49 (1.69--3.66)
  **Cardiac events** [\*](#t006fn002){ref-type="table-fn"}       6           106/9070       75/8560     1.20 (0.89--1.61)    16   95/9070      72/8560      1.27 (0.88--1.83)
  **Pulmonary events** [\*\*](#t006fn003){ref-type="table-fn"}   3           18/2214        25/2177     0.72 (0.40--1.31)    6    24/2214      31/2177      0.77 (0.45--1.32)

**Abbreviation:** ADRs: adverse drug reactions; RR: relative risk; BV: bevacizumab.

\*Cardiac events including: left ventricular (LV) dysfunction and congestive heart failure.

\*\*Pulmonary events including: embolism, dyspnea, pneumonitis and hemorrhages.

ADRs and BV dose {#sec023}
----------------

We assessed whether the higher dose of BV is related to the risk for developing ADRs in cancer patients **([Table 7](#pone.0136324.t007){ref-type="table"})**. When comparing the risk of ADRs between low and high-doses of BV, the RRs of all grade proteinuria (2.64; 95% CI: 1.29--5.40 vs. 9.24; 95% CI: 6.60--12.94) and severe grade bleeding (1.36; 95% CI: 1.05--1.75 vs. 2.87; 95% CI: 1.97--4.18) was increased significantly when switching from 2.5 mg/kg to 5 mg/kg BV. Although not statistically significant, there was a trend towards a higher risk of several side effects (including all grade and severe grade of hypertension, gastrointestinal perforation, thrombocytopenia, diarrhea, neutropenia and febrile neutropenia, all grade epistaxis and severe grade of ADRs including rash, nausea, vomiting, arterial thromboembolic events and cardiac events) in patients using high-dose compared with low-dose BV.

10.1371/journal.pone.0136324.t007

###### Safety subgroup analyses in all trials combined.

![](pone.0136324.t007){#pone.0136324.t007g}

                                                                 All grade               Severe grade                                     
  -------------------------------------------------------------- ----------------------- ------------------------ ----------------------- -----------------------
  **Hypertension**                                               2.66 (2.15--3.29)       4.71 (3.10--7.15)        4.47 (3.05--6.56)       7.48 (5.04--11.10)
  **Bleeding**                                                   2.35 (1.54--3.60)       3.53 (2.43--5.13)        **1.36 (1.05--1.75)**   **2.87 (1.97--4.18)**
  **Gastrointestinal perforation**                               2.07 (0.24--18.04)      2.18 (1.12--4.22)        1.86 (0.98--3.55)       2.44 (1.18--5.04)
  **Proteinuria**                                                **2.64 (1.29--5.40)**   **9.24 (6.60--12.94)**   4.18 (2.67--6.55)       6.42 (3.66--11.26)
  **Epistaxis**                                                  2.95 (2.10--4.15)       4.60 (2.35--8.99)        4.85 (0.23--10.56)      3.71 (1.16--11.86)
  **Stomatitis**                                                 1.91 (1.47--2.48)       1.54 (0.69--3.44)        3.62 (0.88--14.84)      3.22 (2.08--4.97)
  **Rash**                                                       1.80 (0.87--3.72)       1.24 (0.48--3.20)        1.80 (0.69--4.59)       2.77 (1.72--4.45)
  **Neutropenia**                                                1.16 (0.89--1.53)       1.22 (1.04--1.44)        1.03 (0.93--1.14)       1.09 (1.03--1.44)
  **Febrile neutropenia**                                        1.32 (0.30--5.82)       1.52 (1.01--2.30)        1.37 (1.01--1.85)       1.45 (1.21--1.73)
  **Fatigue**                                                    0.93 (0.78--1.11)       1.05 (0.95--1.17)        0.47 (0.27--0.84)       0.68 (0.33--1.37)
  **Nausea**                                                     1.04 (0.88--1.22)       0.98 (0.87--1.11)        1.19 (0.83--1.71)       1.82 (1.33--2.50)
  **Vomiting**                                                   1.07 (0.88--1.30)       0.84 (0.47--1.50)        1.15 (0.83--1.58)       1.69 (1.04--2.74)
  **Thrombocytopenia**                                           1.16 (0.88--1.54)       1.40 (0.96--2.02)        0.94 (0.63--1.40)       1.32 (1.00--1.74)
  **Arterial thromboembolic events**                             1.91 (0.63--5.79)       1.42 (0.72--2.79)        1.50 (0.98--2.29)       2.78 (1.13--6.85)
  **Diarrhea**                                                   1.04 (0.96--1.14)       1.46 (0.89--2.40)        1.21 (1.03--1.42)       1.23 (0.91--1.67)
  **Cardiac events** [\*](#t007fn002){ref-type="table-fn"}       1.33 (0.19--9.55)       1.19 (0.89--1.61)        0.97 (0.48--1.95)       1.45 (0.93--2.27)
  **Pulmonary events** [\*\*](#t007fn003){ref-type="table-fn"}   0.72 (0.38--1.38)       0.72 (0.16--3.19)        0.86 (0.36--1.99)       0.74 (0.27--1.99)

**Abbreviation:** RR: relative risk; BV: bevacizumab.

\*Cardiac events including: left ventricular (LV) dysfunction and congestive heart failure.

\*\*Pulmonary events including: embolism, dyspnea, pneumonitis and hemorrhages.

Sensitivity analysis {#sec024}
--------------------

We performed a sensitivity analysis for all grade and severe grade hypertension and proteinuria excluding the 2 trials \[[@pone.0136324.ref022], [@pone.0136324.ref023]\] concerning patients with renal cancer. The magnitude of association was lower after excluding these trials, but remained robustly significant: for all grade and severe grade hypertension (3.06, 95%CI: 2.47--3.79 and 5.72, 95%CI: 4.35--7.51, respectively) and for all grade (3.12, 95%CI: 1.59--6.13) and severe grade proteinuria (4.43, 95%CI: 3.17--6.20).

QOL {#sec025}
---

QOL was assessed in 7 RCTs \[[@pone.0136324.ref019],[@pone.0136324.ref031],[@pone.0136324.ref036],[@pone.0136324.ref041],[@pone.0136324.ref047],[@pone.0136324.ref048],[@pone.0136324.ref050]\] at baseline and during follow-up until disease progression. We were not able to conduct a meta-analysis for this outcome because QOL was measured using different instruments in different trials. All trials reported that there were no statistically significant differences in the mean change in QOL between patients treated by BV compared to patients treated with chemotherapeutic agents alone.

Discussion {#sec026}
==========

To the best of our knowledge, this is the largest meta-analysis of BV that evaluated both efficacy and safety in different types of solid tumors in cancer patients. Compared to previous published meta-analyses, our study adds relevant information with respect to the identification of predictors of BV risk and benefit through subgroup and meta-regression analyses. This meta-analysis confirmed that the addition of BV to adjuvant therapy leads to improvement in PFS, OS and ORR in all trials combined. This PFS and OS improvement was observed across various tumor types and BV doses, and across different patient or trial characteristics. In contrast, ORR appeared to be influenced by tumor type and BV dose. Despite increased risk of expected ADRs, the addition of BV to adjuvant therapy does not seem to influence QOL. Though not statistically significant, there was a trend towards a higher risk of several ADRs in patients using high-dose BV compared to patients treated with low-dose.

The quality of each included RCT was assessed by applying the Cochrane Collaboration's tool, which is a validated assessment instrument. The results showed a high risk of bias in domain of blinding for both primary and secondary outcomes, however because in cancer trials most outcomes (like OS and PFS) are not likely to be influenced by lack of blinding the overall quality of all trials combined was considered to be acceptable \[[@pone.0136324.ref052]\]. Lack of blinding might have influenced the results of the QOL analyses, and therefore such results should be interpreted with caution.

We demonstrated improvement in PFS in patients with all types of tumors except for patients with melanoma, mesothelioma or cervical cancers. In spite of OS improvement when all trials were combined, no significant OS advantage was observed in certain types of cancer e.g. breast cancer and ovarian cancer although there were trends in the correct direction. Even after adding several new trials to the meta-analyses our findings continued to show this lack of OS benefit in breast cancer \[[@pone.0136324.ref004], [@pone.0136324.ref053]\] and ovarian cancer \[[@pone.0136324.ref054]\]. A possible explanation according to Broglio et al \[[@pone.0136324.ref055]\] is that when SPP is long, for example 15.6 months for breast cancer and 21.1 months for ovarian cancer, it is more difficult to show improvement in OS. While in trials with a short SPP such as for colorectal cancer (10.6 months) and NSCLC (9.2 months) there is usually a statistically significant benefit in OS if there is a statistically significant treatment benefit in PFS.

On the other hand, surrogacy of PFS for OS in different cancer types has been evaluated in several studies with different results \[[@pone.0136324.ref056], [@pone.0136324.ref057]\]. In the current study, a significant moderate correlation between PFS and OS was observed in all combined trials which is consistent with the results of previous studies. Therefore, in clinical trials with a PFS benefit, lack of statistical significance in OS does not necessarily mean a lack of improvement in OS.

Our study also suggests that the relationship between PFS and OS varies considerably by cancer type. The correlation between PFS and OS was more pronounced in trials of breast cancer compared with colorectal cancer and in NSCLC there was a surprisingly negative correlation. In breast cancer and colorectal cancer, our results are in line with the results of previous studies \[[@pone.0136324.ref058], [@pone.0136324.ref059]\] while in NSCLC there is evidence for a positive relationship between PFS and OS \[[@pone.0136324.ref060]\].Most malignant tumors are highly dependent on angiogenesis, therefore it is as expected that BV added to standard chemotherapies substantially improves the ORR in different tumor types.

The dose of BV used in adjuvant therapy was not found to be associated with PFS or OS benefit, consistent with a prior meta-analysis \[[@pone.0136324.ref004]\]. However, our findings showed that the ORR benefit varied significantly by tumor type. The highest ORR was observed in renal cancer patients, while gastric cancer patients benefited the least of BV treatment. Thus, tumor type likely plays an important role in the response to BV. This variation in response may also be partly due to the combination of BV with different chemotherapeutic agents in different tumor types. However, other reasons might be differences in the number of studies and power of the studies for the different tumor types. Further research is warranted into which tumors benefit most from BV therapy.

Although not significant, there was a trend towards a higher ORR in patients using a high-dose BV compared with patients using a low-dose in all trials combined, in colorectal cancer and in breast cancer trials. The increase in ORR with high-dose BV may have been due to improved BV-induced drug delivery to the tumor site. Our results are in line with the results of previous studies that showed a dose-response relationship in NSCLC and metastatic renal cell carcinoma \[[@pone.0136324.ref061], [@pone.0136324.ref062]\], but not in colorectal cancer \[[@pone.0136324.ref014]\]. A significantly higher improvement in ORR found in 61--65 years old patients compared with all other age groups in all trials combined and in colorectal cancer trials has no biological or clinical explanation, and is likely a chance finding. An important consideration is the timing of response assessment: the results in the colorectal cancer studies showed a higher ORR in favor of BV if response was assessed between 8--12 weeks compared with 6 weeks. A longer time to response assessment is likely to capture slower tumor responses and be more complete, important for non-cytotoxic agents such as BV.

Our results showed that some ADRs were more common in patients randomized to BV. This is consistent with those of prior safety meta-analyses linking specific ADRs to BV therapy \[[@pone.0136324.ref003],[@pone.0136324.ref053],[@pone.0136324.ref063]--[@pone.0136324.ref071]\]. BV significantly reduced the risk of both all grade and severe grade anemia compared with adjuvant therapy alone in cancer patients with no significant variation among different BV doses which was in line with previous meta-analysis \[[@pone.0136324.ref065]\]. Several possibilities related to VEGF inhibition may explain the effect of BV on anemia. BV has been shown to promote hepatic erythropoietin (EPO) synthesis and erythrocytosis in preclinical models \[[@pone.0136324.ref072]\]; also, it may cause tissue hypoxia due to its anti-angiogenesis and vasoconstriction effect, leading to subsequent up-regulation of erythropoietin. Furthermore, we showed that the addition of BV to standard adjuvant therapy was associated with reduced risk of severe grade fatigue in cancer patients compared to those who were treated by adjuvant therapy alone. Increase in several inflammatory markers is associated with an increase in fatigue among cancer patients during and after cancer treatment \[[@pone.0136324.ref073]\], so BV may reduce these inflammatory markers via an unknown mechanism; alternatively, this may be associated with a reduction in anemia. Since this finding has not been reported before it might be interesting for future research.

Our study adds information to existing literature about the increased risk for the following ADRs: febrile neutropenia, stomatitis, vomiting, nausea and rash as well as decreased risk for severe grade fatigue.

In our study, the most frequent ADRs of BV was hypertension which represents a common finding across 40 trials. Infusion of VEGF has been found to produce hypotension \[[@pone.0136324.ref074]\] and thus blockade of VEGF may potentially lead to elevation of blood pressure.

We also investigated the associations of BV with ADRs according to different BV dose. Our study indicated a dose dependency although not significantly for the association of most ADRs with BV therapy. Moreover, a significant higher risk of all-grade proteinuria and severe grade bleeding was observed in patients who received high-dose compared with patients treated with low-dose BV (RR: 9.24 vs. 2.64) and (2.87 vs. 1.36), respectively which is in agreement with previous meta-analyses \[[@pone.0136324.ref001],[@pone.0136324.ref002]\].

In this study, the following limitations were acknowledged: This study was conducted using published RCTs not individual patient data. Our meta-analysis pooled trials with heterogeneous cancer types and different patient populations, BV doses, antineoplastic agents used, follow-up durations and the timing of response assessment, although by applying a random-effects model we took possible heterogeneity into account. In this meta-analysis we have decided not to include studies on glioblastoma because in this kind of tumor, drug delivery is different from the other types of cancer that were studied. Furthermore, we only compared the efficacy and safety of BV with standard chemotherapy agents not with radiotherapy and other types of anti-neoplasms.

As in all meta-analyses, our results may be biased as a result of potential publication bias however; a funnel plot evaluation for the primary endpoints did not indicate serious publication bias. Finally, most of trials did not report outcomes separately by patient's gender, so we were not being able to perform a subgroup analysis to evaluate a potential gender treatment interaction.

In summary, this meta-analysis extends the results of previous RCTs and meta-analyses which show a benefit of adding BV to adjuvant therapy compared to patients who received adjuvant therapy alone, but finding no interaction with baseline characteristics or with dose of BV. In contrast, patients treated with high-dose BV had more ADRs but without significant changes in measured QOL. Future studies are needed to evaluate the efficacy and safety of the addition of other angiogenesis inhibitors to standard chemotherapy agents and to compare these results with the effect of BV on PFS and OS.
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